Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Therapy Study XV for Newly Diagnosed ALL
NCT00137111Phase 3Completed
- Sponsor
- St. Jude Children's Research Hospital
- Start
- Jul 2000
- Primary completion
- Nov 2010
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of methotrexate in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by St. Jude Children's Research Hospital. Primary endpoints: Overall Event-free Survival at 5.6 years and Continuous Complete Remission Since Week 56 Therapy at 4.5 years. Started Jul 2000; status: completed.
02
Drugs
methotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT00137111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00137111.